Skip to content

Chimeron Bio

1 viewer · 30d

Total raised

$12.8M

1 filing since 2024 · latest Equity filed

Cumulative raised
LAST ROUND
Equity · $12.8M
ROUNDS
1
INVESTORS
9
FOUNDED
N/A
HQ
Philadelphia, PA
SECTOR
Biotech
EMPLOYEES
N/A
30D VIEWERS
1

AI overview

Updated

Chimeron Bio Corp is a forward-thinking biotechnology company headquartered in Philadelphia, focused on the innovation of RNA-based therapeutics and vaccines. Through its proprietary ChaESAR™ platform, the company seeks to enhance the effectiveness of RNA medicines by leveraging self-amplifying RNA technology to create treatments that are more potent and long-lasting than traditional mRNA solutions.

What sets it apart

Chimeron Bio stands out with its ChaESAR™ platform, which significantly improves the potency and duration of RNA-based therapies while simplifying the manufacturing process.

Funding history

1 round
EquityMar 25, 2024
Form D/A
+$12.8M$12.8M total

Latest SEC filings

via EDGAR · CIK 0001837360
Form D/A · Mar 25, 2024View on EDGAR

Products

1 tracked

ChaESAR™ Platform

Biotechnology Platform

The ChaESAR™ platform is a proprietary technology that employs self-amplifying RNA (saRNA) to develop potent RNA-based therapeutics and vaccines. This platform enhances the efficacy and longevity of treatment effects while reducing the necessary dosage and simplifying the production and distribution processes.

  • Self-amplifying RNA technology
  • Increased potency compared to traditional mRNA
  • Longer-lasting therapeutic effects
  • Lower dosage requirements

Links

WebsiteSEC EDGAR filings